Sarilumab, a fully human monoclonal antibody against IL-6R αin patients with rheumatoid arthritis and an inadequate response to methotrexate: Efficacy and safety results from the randomised SARIL-RA-MOBILITY part a trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 9, 2014, Pages 1626-1634

  Huizinga, Tom W J ^a   Fleischmann, Roy M ^b   Jasson, Martine ^c   Radin, Allen R ^d   Van Adelsberg, Janet ^d   Fiore, Stefano ^c   Huang, Xiaohong ^c   Yancopoulos, George D ^d   Stahl, Neil ^d   Genovese, Mark C ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c SANOFI   (France)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINES; DMARDS (BIOLOGIC); RHEUMATOID ARTHRITIS; TREATMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84905179575     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204405     Document Type: Article

References (38)

1. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 6):vi28-36.
2. Katchamart W, Trudeau J, Phumethum V, et al. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2010;(4):CD008495.
3. Enbrel (etanercept) prescribing information. http://pi.amgen.com/united- states/enbrel/derm/enbrel-pi.pdf. (accessed 23 Jul 2013).
4. REMICADE (infliximab) prescribing information. http://www.remicade.com/ remicade/assets/hcp-ppi.pdf (accessed 23 Jul 2013).
5. HUMIRA (adalimumab) prescribing information. http://www.rxabbott.com/pdf/ humira.pdf (accessed 23 Jul 2013).
6. SIMPONI (golimumab) prescribing information. http://www.simponi.com/ sites/default/files/pdf/prescribing-information.pdf (accessed 23 July 2013).
7. CIMZIA (certolizumab pegol) prescribing information. http://cimzia.com/ pdf/Prescribing-Information.pdf (accessed 23 Jul 2013).
8. Kineret (anakinra) prescribing information. http://www.accessdata.fda. gov/drugsatfda-docs/label/2003/anakamg062703LB.pdf (accessed 23 July 2013).
9. ORENCIA (abatacept) prescribing information. http://packageinserts.bms. com/pi/pi-orencia.pdf (accessed 23 Jul 2013).
10. RITUXAN (rituximab) prescribing information. http://www.gene.com/gene/ products/information/pdf/rituxan-prescribing.pdf (accessed 23 Jul 2013).
11. Actemra (tocilizumab) Prescribing Information 2010. http://www.gene.com/ gene/products/information/actemra/pdf/pi.pdf (accessed 23 Jul 2013).
12. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
13. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010;2:247-56.
14. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
15. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
16. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
17. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012;71:687-93.
18. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
19. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
20. Genovese MC, Fleischmann RM, Fiore S, et al. Sarilumab, a subcutaneously-administered, fully-human monoclonal antibody inhibitor of the IL-6 receptor: Relationship between EULAR responses and change from baseline of selected clinical parameters. Ann Rheum Dis 2013;72(Suppl 3):620.
21. Zhang L, Luan B, Adler A, et al. Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker aflibercept. Cancer Res 2012;72(8 Suppl 1):2723. doi:10.1158/1538-7445.AM2012-2723.
22. Wang L-H, Xue Y, Liu X, et al. Preclinical development of sarilumab, the first fully human monoclonal antibody (mAb) against IL-6R alpha: utilization and value of double humanized animal model. Ann Rheum Dis 2013;72(Suppl 3):375.
23. Rafique A, Martin J, Blome M, et al. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6R) alpha. Ann Rheum Dis 2013;72(Suppl 3):797.
24. Radin AR, Mellis SJ, Jasson M, et al. REGN88/SAR153191, a fully-human interleukin-6 receptor monoclonal antibody, reduces acute phase reactants in patients with rheumatoid arthritis: preliminary observations from Phase 1 studies. Arthritis Rheum 2010;62(Suppl 10):S470.
25. Radin A, Mellis S, Jasson M, et al. Safety and effects on markers of inflammation of subcutaneously administered REGN88/SAR153191, an interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis: findings from Phase 1 studies. Ann Rheum Dis 2010;69(Suppl 3):99.
26. Huizinga TW, Kivitz AJ, Rell-Bakalarska M, et al. Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: results of a phase 2, randomized, doubleblind, Placebo-Controlled, International Study. Ann Rheum Dis. 2012;71(Suppl 3):60.
27. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
28. Felson DT, Anderson JJ, Boers M, et al American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-35.
29. Fransen J, Stucki G, van Riel PLCM. Rheumatoid arthritis measures: disease activity score (DAS), disease activity score-28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI). Arthritis Care Res 2003;49(S5):S214-24.
30. Belomestnov P, Hamilton J, DiCioccio AT, et al. Sarilumab, a subcutaneously-administered, fully-human monoclonal antibody inhibitor of the IL-6 receptor: pharmacokinetic profile and its relationship to changes in pharmacodynamic markers in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:S576.
31. Fleischmann R, Fiore S, Fan C, et al. Sarilumab, a fully human mAb against IL-6R alpha, subcutaneously-administered shows significant improvement in RA patients as early as 2 weeks: a time to event analysis for ACR50 and EULAR good response. Ann Rheum Dis 2013;72(Suppl 3):627.
32. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
33. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29. (Pubitemid 44497760)
34. Shakib S, Francis B, Smith J, et al. Safety, pharmacokinetics and pharmacodynamics of ALD518 (BMS-945429), a high-affinity monoclonal antibody directed against interleukin-6 (IL-6) administered by subcutaneous injection: a phase I trial. [abstract]. Arthritis Rheum 2010;62(Suppl 10):1124.
35. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
36. Choy E, Sattas N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
37. Navarro-Millán I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 2013;65:1430-8.
38. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. (Pubitemid 30165206)